What is EDDA Technology?
Established in 2003 and headquartered in New Jersey, EDDA Technology specializes in the development of sophisticated computer-assisted solutions designed to optimize the patient care management cycle. The company's core competency lies in its ability to integrate advanced imaging analytics with clinical workflows, facilitating the early detection and precise diagnosis of complex diseases. By providing clinicians with actionable insights, EDDA Technology effectively bridges the gap between raw diagnostic data and improved patient outcomes. Its market position is defined by a commitment to high-precision medical technology, serving as a critical infrastructure provider for modern healthcare institutions seeking to enhance diagnostic accuracy and operational efficiency.
How much funding has EDDA Technology raised?
EDDA Technology has raised a total of $150.3M across 2 funding rounds:
Debt
$350K
Other Financing Round
$150M
Debt (2020): $350K with participation from PPP
Other Financing Round (2021): $150M led by OrbiMed, The Bridge, SoftBank Group Corp., BOCGI, Sbcvc, Draper Dragon, The Morningside Group, 3W Fund, and Matrix Partners China
Key Investors in EDDA Technology
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various stages of development.
SoftBank Group Corp.
SoftBank Group Corp. is a global technology holding company that leverages its Vision Fund to back transformative businesses in AI, robotics, and internet services, fostering long-term growth and industry leadership.
Draper Dragon
Draper Dragon is a cross-border venture fund connecting Silicon Valley and Asia, focusing on early-stage companies and leveraging two decades of experience to empower startups redefining global industries.
What's next for EDDA Technology?
With the successful closure of its latest financing round, EDDA Technology is poised to expand its footprint in the competitive healthcare AI market. The strategic focus will likely center on scaling its enterprise-grade diagnostic tools and deepening its integration within existing hospital information systems. As the demand for automated, AI-driven clinical decision support continues to rise, the company is expected to leverage its recent capital to enhance its R&D capabilities and pursue broader international market adoption. The involvement of high-profile institutional backers suggests a long-term strategy aimed at establishing EDDA Technology as a standard-bearer for digital diagnostic excellence in the global medical community.
See full EDDA Technology company page
